One-month dual antithrombotic strategy after PCI reduced bleeding without higher 12‑month thromboembolic risk in OPTIMA‑AF trial
OPTIMA‑AF found that stopping dual antithrombotic therapy after one month and continuing a DOAC alone reduced bleeding without raising 12‑month death or thromboembolism.